Clinical Trials

Keywords/SWOG Study Number

Area of Research

Accrual Status

Any

Open

Closed

Limit to SWOG Trials

All Trials

SWOG Trials Only

Show only published studies

Study Type

Treatment

Study Chair

Participating Institution

Phase

Cancer Control Subcommittee

Study Sponsor

FDA Registration Trial

Uses PRO Forms

1033 Results

View

Closed

Phase

Accrual

100%

Published

SWOG Clinical Trial Number

S0722

A Phase II Trial of mTOR Inhibitor, Everolimus, (RAD001) in Malignant Pleural Mesothelioma (MPM)

Research Committee(s)

Lung Cancer

Activated

12-01-2008

Closed

09-15-2011

Closed

Phase

Accrual

100%

Published

SWOG Clinical Trial Number

S0720

Phase II ERCC 1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

Research Committee(s)

Lung Cancer

Activated

11-15-2008

Closed

05-15-2012

Closed

Phase

Accrual

100%

SWOG Clinical Trial Number

S0711

Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction."

Research Committee(s)

Early Therapeutics & Rare Cancers

Activated

10-15-2008

ClinicalTrials.gov Registry Number

NCT00608361

Closed

Phase

Accrual

SWOG Clinical Trial Number

S0307A

Long-Term Bone Quality in Women With Breast Cancer (A Companion Study to S0307)

Research Committee(s)

Breast Cancer

Activated

10-01-2008

Closed

02-01-2010

Closed

Phase

Accrual

SWOG Clinical Trial Number

S0629

Observational study of asymptomatic Waldenström’s Macroglobulinemia and Phase II study of tandem autologous transplant and maintenance treatment for patients with symptomatic disease

Research Committee(s)

Myeloma

Activated

09-15-2008

Closed

Phase

Accrual

SWOG Clinical Trial Number

S0717

A Phase I and A Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) with or without MEDI-522 (NSC-719850)

Research Committee(s)

Genitourinary Cancer

Activated

06-15-2008

Closed

04-01-2009

Closed

Phase

Accrual

100%

Published

SWOG Clinical Trial Number

S0000D

S0000D, "A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT, Phase III Ancillary to S0000-SELECT

Activated

06-03-2008

Closed

05-28-2013

ClinicalTrials.gov Registry Number

NCT00706121

Closed

Phase

Accrual

Published

SWOG Clinical Trial Number

S0502

A Phase III Randomized Study of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors

Research Committee(s)

Gastrointestinal Cancer

Activated

04-15-2008

Closed

10-01-2009

ClinicalTrials.gov Registry Number

NCT00324987

Closed

Phase

Accrual

100%

Published

SWOG Clinical Trial Number

S0777

A Randomized Phase III Trial of CC-5013 (lenalidomide, NSD-703813) and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant

Status Notes

Revision #24 requires sites to contact all patients that have been enrolled, including those that have completed treatment and follow-up, to offer them participation in extended follow-up.

Research Committee(s)

Myeloma

Activated

04-01-2008

Closed

02-01-2012

Closed

Phase

Accrual

100%

Published

SWOG Clinical Trial Number

S0727

A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First Line Treatment in Patients with Metastatic Pancreatic Cancer

Research Committee(s)

Gastrointestinal Cancer

Activated

03-01-2008

Closed

09-01-2010

ClinicalTrials.gov Registry Number

NCT00617708

Closed

Phase

Accrual

100%

Published

SWOG Clinical Trial Number

S0518

Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Research Committee(s)

Gastrointestinal Cancer

Activated

12-01-2007

Closed

09-01-2012

ClinicalTrials.gov Registry Number

NCT00569127

Closed

Phase

Accrual

100%

SWOG Clinical Trial Number

S0535

A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia

Research Committee(s)

Leukemia

Activated

11-15-2007

ClinicalTrials.gov Registry Number

NCT00551460

Closed

Phase

Accrual

91%

Published

SWOG Clinical Trial Number

S0438

A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma

Research Committee(s)

Melanoma

Activated

08-01-2007

Closed

11-15-2009

Closed

Phase

Accrual

100%

SWOG Clinical Trial Number

S0337

A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer

Research Committee(s)

Genitourinary Cancer

Activated

07-15-2007

Closed

08-15-2012

ClinicalTrials.gov Registry Number

NCT00445601

Closed

Phase

Accrual

95%

SWOG Clinical Trial Number

S0635

A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features

Research Committee(s)

Lung Cancer

Activated

07-15-2007

Closed

08-15-2011

Closed

Phase

Accrual

100%

SWOG Clinical Trial Number

S0636

A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas

Research Committee(s)

Lung Cancer

Activated

07-15-2007

Closed

09-01-2010

Closed

Phase

Accrual

11%

Published

SWOG Clinical Trial Number

S0600

Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX

Research Committee(s)

Gastrointestinal Cancer

Activated

06-15-2007

Closed

11-10-2010

ClinicalTrials.gov Registry Number

NCT00499369

Closed

Phase

Accrual

19%

Published

SWOG Clinical Trial Number

S0521

A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III

Research Committee(s)

Leukemia

Activated

06-01-2007

ClinicalTrials.gov Registry Number

NCT00492856

Closed

Phase

Accrual

100%

Published

SWOG Clinical Trial Number

S0354

A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6) in Patients with Hormone Refractory Prostate Cancer

Research Committee(s)

Genitourinary Cancer

Activated

04-01-2007

Closed

05-15-2008

Closed

Phase

Accrual

100%

Published

SWOG Clinical Trial Number

S0622

Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer

Research Committee(s)

Breast Cancer

Activated

03-15-2007

Closed

12-15-2010